Dermatology Treatment & Research Center

Dermatology Treatment & Research Center is currently looking for patients with the following conditions to participate in research studies: Psoriasis,Acne, Rosacea and Atopic Dermatitis / Eczema. If you don’t see your dermatological condition listed below please call 972-661-2729 ext 227 as we continue to get new studies.

Psoriasis:

Must be 18 years of age or older

Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug.

Currently be moderate to severe, with 10% or more of the body surface covered with plaque-type psoriasis.

If of child bearing potential, must be willing to use adequate contraceptive for the duration of study participation.

Must be willing to comply with all study requirements including but not limited to: chest x-ray, ECGs, and multiple blood draws throughout the study.

Cannot be currently treating or if treating psoriasis is not adequately being controlled by current treatment and subjects is willing to stop taking (washout can be 2-12 weeks) prior to starting study medication.

Cannot have any other type of psoriasis (i.e. erythrodermic, pustular, or guttate).

Cannot have any other skin condition that may interfere with psoriasis assessments.

Cannot have ever used Raptiva.

A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-1004) in Subjects with moderate to severe plaque psoriasis. (4-52 weeks)

Must be 18 years of age or older

Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug.

Currently be moderate to severe, with 10% or more of the body surface covered with plaque-type psoriasis.

If of child bearing potential, must be willing to use adequate contraceptive for the duration of study participation.

Must be willing to comply with all study requirements including but not limited to: chest x-ray, ECGs, and multiple blood draws throughout the study.

Cannot be currently treating or if treating psoriasis is not adequately being controlled by current treatment and subjects is willing to stop taking (washout can be 2-12 weeks) prior to starting study medication.

Cannot have any other type of psoriasis (i.e. erythrodermic, pustular, or guttate).

Cannot have any other skin condition that may interfere with psoriasis assessments.

A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis area and severity index (PASI) response and maintenance of response in Subjects with moderate to severe chronic plaque-type psoriasis on either a fixed regimen or on a retreatment at start of relapse regimen. (60 weeks)

Must be 18 years of age or older

Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 6 months prior to first dose of study drug.

Currently be moderate to severe, with 10% or more of the body surface covered with plaque-type psoriasis.

If of child bearing potential, must be willing to use adequate contraceptive for the duration of study participation.

Must be willing to comply with all study requirements including but not limited to: chest x-ray, ECGs, and multiple blood draws throughout the study.

Cannot be currently treating or if treating psoriasis is not adequately being controlled by current treatment and subjects is willing to stop taking (washout can be 2-12 weeks) prior to starting study medication.

Cannot have any other type of psoriasis (i.e. erythrodermic, pustular, or guttate).

Cannot have any other skin condition that may interfere with psoriasis assessments.

A National, Multi-Center, Prospective, Non-Controlled, Open, Single-Group, 8-Week study in Adolescent Subjects (aged 12-17 years) with Scalp Psoriasis, Evaluating the safety and efficacy of once daily use of the LEO 80185 topical suspension containing calcipotriol 50mg/g plus betamethasone 0.5mg/g (as dipropionate) in adolescent (aged 12-17 years) with scalp psoriasis.

A clinical diagnosis of Psoriasis Vulgaris.

Currently under the care of a dermatologist for their psoriasis.

Must be willing to be at the office no later than 7:30am on visits 2, 5, 7 and 9 to complete ACTH challenge test.

Be willing to keep a food diary.

Be willing to collect 24hr urine (no Friday appointments due to 24hr urine).

Be willing to answer questionnaires regarding their condition.

Willing and able to attend all 9 appointments.

A 10-Year Post-Marketing, observational Registry of Humira (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis (Ps).

Adults 18 and over with chronic plaque Psoriasis who has been prescribed Humira (Adalimumab) therapy and meets one of the following criteria:

Newly initiated (within 4 weeks of registry entry) on Humira therapy

Initiated Humira therapy in the past and:

Has received continuous (no more than 70 consecutive days off drug) Humira therapy.

Patient visits should co-inside with their normal 3 month follow up visits with the clinic.

Visits will be every six months with the exception of the second visit (visit after enrollment) which will be 3 months after signing consent, visits will then be scheduled every 6 months (from consent date) until the patient completes the 10 year study or should chose to withdraw consent.

If a patient should move out of the area we can help transfer their information so that they can continue in the study at a location near to their new home.

An 8-10 year Multi-center, Open Registry of Patients who are Candidates for Systemic Therapy Including Biologics.

Adults 18 and older with a clinical diagnosis of Psoriasis

Are Candidates for or are currently receiving Stelara (ustekinumab)

Patients who are currently treating their psoriasis with one of the following medications or therapies:

Conventional systemic agents (e.g. methotrexate, acitretin, cyclosporine, fumarates, or systemic PUVA)

Biologic therapy agents (e.g. Enbrel (etanercept) or Humira (Adalimumab))

Patients with severe plaque psoriasis and treating with Remicade (infliximab)

Visits will be every six months with the exception of the second visit (visit after enrollment) which will be 3 months after signing consent, visits will then be scheduled every 6 months (from consent date) until the patient completes the 10 year study or should chose to withdraw consent.

If a patient should move out of the area we can help transfer their information so that they can continue in the study at a location near to their new home.

Atopic Dermatitis:

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multiple Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered REGN668 in Adolescents and Adults with Moderate-to-Severe Extrinsic Atopic Dermatitis.

Males or Females 18 years and older

Clinical diagnosis of Chronic Atopic Dermatitis that has been present for at least 3 years

Willing to stop current medications used for Atopic Dermatitis

Willing and able to comply with clinic visits and study related procedures (eg, blood draws, Chest X-Rays, ECGs)

No history of a doxycycline allergy

Cannot be pregnant or currently Breast feeding, and willing to use study approved birth control throughout the duration of the study.

 Athlete’s Foot:

Please take our Survery to see if you Qualify (CLICK HERE)
A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-blinded comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects with interdigital tinea pedis. (5-6 weeks)

Must be 12 years of age or older (parent must be present for consent for anyone under the age of 18)

Must have red, itchy, flaky skin between the toes.

Must be willing to comply with all study requirements including but not limited to: skin scrapings, and multiple blood draws throughout the study.

Cannot be pregnant or breast feeding.

Up Coming Studies:

Rosacea (testing a topical medication)

Acne (testing a topical medication)

Discoid Lupus (testing an oral medication)

Descriptions of some dermatological diseases:

Acne:

Non-Inflammatory Acne: Non-inflamed acne breakouts consist of microcomedones, blackheads, and milia. These types of comedones are not red or painful. Symptoms of non-inflamed acne include bumps or bumpiness across the skin's surface, or an uneven skin texture. Even if comedones are not readily visible, they will make the skin feel rough or "sandpapery." People with non-inflamed acne experience blackheads, milia, and closed comedones but rarely have reddened breakouts, such as papules or pustules. Left untreated, non-inflamed acne may progress to inflamed acne.

Inflammatory Acne: is characterized by redness and inflammation. Those with inflamed acne will have microcomedones, blackheads, and milia, as well as papules, pustules, and possibly nodules and cysts. Symptoms also include redness, swelling, and irritation of the skin, along with possible crusting, oozing, or scabbing of the lesions. Inflamed acne ranges in acuity from very mild to extremely severe. Some inflamed acne sufferers will experience only the occasional pustule while others will battle angry-looking cysts. Cystic acne is the most serious form of inflamed acne. Inflamed acne sufferers are most at risk for skin damage and scarring.

Psoriasis:

Plaque psoriasis. The most common form, plaque psoriasis causes dry, raised, red skin lesions (plaques) covered with silvery scales. The plaques itch or may be painful and can occur anywhere on your body, including your genitals. You may have just a few plaques or many, and in severe cases, the skin around your joints may crack and bleed.

Nail psoriasis. Psoriasis can affect fingernails and toenails, causing pitting, abnormal nail growth and discoloration. Psoriatic nails may become loose and separate from the nail bed (onycholysis). Severe cases may cause the nail to crumble.

Scalp psoriasis. Psoriasis on the scalp appears as red, itchy areas with silvery-white scales. You may notice flakes of dead skin in your hair or on your shoulders, especially after scratching your scalp.

Guttate psoriasis. This primarily affects people younger than 30 and is usually triggered by a bacterial infection such as strep throat. It's marked by small, water-drop-shaped sores on your trunk, arms, legs and scalp. The sores are covered by a fine scale and aren't as thick as typical plaques are. You may have a single outbreak that goes away on its own, or you may have repeated episodes.

Inverse psoriasis (flexural). Mainly affecting the skin in the armpits, groin, under the breasts and around the genitals, inverse psoriasis causes smooth patches of red, inflamed skin. It's more common in overweight people and is worsened by friction and sweating.

Pustular psoriasis. This uncommon form of psoriasis can occur in widespread patches (generalized pustular psoriasis) or in smaller areas on your hands, feet or fingertips. It generally develops quickly, with pus-filled blisters appearing just hours after your skin becomes red and tender. The blisters dry within a day or two but may reappear every few days or weeks. Generalized pustular psoriasis can also cause fever, chills, severe itching and fatigue.

Erythrodermic psoriasis. Erythrodermic psoriasis can cover your entire body with a red, peeling rash that can itch or burn intensely. It may be triggered by severe sunburn, by corticosteroids and other medications, or by another type of psoriasis that's poorly controlled.

Psoriatic arthritis. In addition to inflamed, scaly skin, psoriatic arthritis causes pitted, discolored nails and the swollen, painful joints that are typical of arthritis. It can also lead to inflammatory eye conditions such as conjunctivitis. Symptoms range from mild to severe. It can cause stiffness and progressive joint damage that in the most serious cases may lead to permanent deformity.

Rosacea: Typical signs and symptoms of rosacea include facial flushing, blushing, redness, burning, red bumps, and small cysts. The symptoms tend to come and go. The skin may be clear for weeks, months, or years and then erupt again. Rosacea tends to evolve in stages and typically causes inflammation of the skin of the face, particularly the forehead, cheeks, nose, and chin.

Atopic Dermatitis: Although symptoms may vary from person to person, the most common symptoms are dry, itchy, red skin. Itch is the grand hallmark of the disease. Typical affected skin areas include the folds of the arms, the back of the knees, wrists, face, and hands. Less commonly there may be cracks behind the ears, and various other rashes on any part of the body. Distribution varies with age.